The H1 pic­ture: Biotech’s vi­tal signs show some life — with one big ex­cep­tion

This past six months, the num­bers have start­ed to track up­ward in biotech — and we’re not just talk­ing about M&A here.

We’re start­ing to see re­al ev­i­dence that VCs — at least the core group that helped ush­er in the Covid boom — are not just sup­port­ing the hardi­est sur­vivors. We’re see­ing a def­i­nite uptick in launch rounds while Big Phar­ma con­tin­ues to put its mon­ey where the best hu­man da­ta are.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.